Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
What are the risks of treating locally advanced pancreatic cancer with chemoradiation with duodenal stent in place due to malignant obstruction?
Is there increased toxicity in patients with duodenal stents receiving RT?
Answer from: Radiation Oncologist at Academic Institution
There is no increased risk from radiation treatment when a duodenal stent is in place.
Sign in or Register to read more
11732
Related Questions
Would you offer postoperative RT for pT2pN0 rectal cancer with close distal margin (within 2 mm) and only 6 lymph nodes obtained from surgery?
Would you consider SBRT to a single nodal recurrence in a patient with previously treated metastatic GEJ adenocarcinoma s/p a complete response to systemic therapy followed by 37.5 Gy to the primary who was NED for 12 months up until this recurrence?
In a patient with metastatic colorectal cancer to the lung and liver, is there a role for liver directed therapy if the lung is not amenable to local therapy?
Would you consider long course pelvic CRT after neoadjuvant chemotherapy in a patient with low lying, locally advanced rectal adenocarcinoma when you're unable to meet small bowel constraints?
In patients with unresectable, liver-limited neuroendocrine tumors (NETs), what clinical or radiographic criteria guide your decision to prioritize systemic therapy over locoregional approaches?
Do you use different dose constraints for large bowel vs. small bowel?
In patients with perihilar cholangiocarcinoma eligible for liver transplant, what is the protocol for neoadjuvant chemo-RT, particularly when brachytherapy is not available?
Would you offer inguinal nodal RT to a patient with anal SCC (pT1N1a, + inguinal node) following APR in the setting of prior prostate + pelvic nodal radiation?
How do you manage persistent rectal bleeding in the setting of rectal adenocarcinoma in a treatment-naive patient?
Do you use more stringent liver constraints when treating HCC with SBRT in patients who are CP B8/9 or C?